Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Oramed Pharmaceuticals Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ORAMED LEVERAGES ITS STRATEGIC CAPITAL MARKETS EXPERTISE TO SUPPORT ALPHA TAU'S BREAKTHROUGH CANCER THERAPY TECHNOLOGY ACCELERATING MULTIPLE LATE-STAGE CANCER THERAPIES INCLUDING: US CLINICAL TRIALS ACROSS FOUR INDICATIONS, MANUFACTURING SCALE-UP, AND COMMERCIALIZATION EFFORTS PARTNERSHIP UNITES TWO INNOVATIVE THERAPEUTIC DELIVERY PIONEERS  ORAMED'S ORAL DRUG DELIVERY PLATFORM WITH ALPHA TAU'S PRECISION RADIATION DELIVERY TECHNOLOGY NEW YORK , APRIL 28, 2025 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. ("ORAMED" OR THE "COMPANY"), (NASDAQ: ORMP) (TASE: ORMP), A PLATFORM TECHNOLOGY PIONEER IN THE FIELD OF ORAL DELIVERY SOLUTIONS FOR DRUGS CURRENTLY DELIVERED VIA INJECTION, ANNOUNCED TODAY THAT IT HAS SUCCESSFULLY CLOSED A STRATEGIC INVESTMENT IN ALPHA TAU MEDICAL LTD. (NASDAQ: DRTS), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART.

ORAMED PHARMACEUTICALS ANNOUNCES $36.9 MILLION INVESTMENT AND STRATEGIC COLLABORATION WITH ALPHA TAU MEDICAL

JERUSALEM, APRIL 28, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE COMPANY) (NASDAQ: DRTS, DRTSW), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, ANNOUNCED TODAY THAT IT HAS SUCCESSFULLY CLOSED A REGISTERED DIRECT OFFERING (THE OFFERING) WHEREBY AN AFFILIATE OF ORAMED PHARMACEUTICALS INC. (ORAMED) (NASDAQ: ORMP) (TASE: ORMP) PURCHASED 14,110,121 OF ALPHA TAU'S ORDINARY SHARES, NO PAR VALUE, AT A PURCHASE PRICE OF $2.612 PER ORDINARY SHARE.

ALPHA TAU ANNOUNCES CLOSING OF $36.9 MILLION REGISTERED DIRECT OFFERING AND STRATEGIC MARKETING ALLIANCE WITH ORAMED PHARMACEUTICALS

KEY HIGHLIGHTS  EXPECTED COMPLETION IN YR 2025: ORATECH PHARMACEUTICALS INC. - A NEW JOINT VENTURE FOCUSED ON ORAL INSULIN DEVELOPMENT, WITH PLANNED U.S. PHASE 3 TRIALS. DISTRIBUTION OF MAJORITY OF ORAMED'S HOLDING IN ORATECH TO ORAMED SHAREHOLDERS VIA DIVIDEND PLANNED TO COINCIDE WITH ORATECH'S PUBLIC LISTING.

ORAMED PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS

NEW STANDALONE COMPANY, ORATECH PHARMACEUTICALS INC., TO FOCUS ON ORAL DRUG DELIVERY WITH STRATEGIC INVESTMENT AND ADVANCED MANUFACTURING CAPABILITIES ORAMED SHAREHOLDERS TO RECEIVE THE RIGHT TO A DIRECT STAKE IN ORATECH, EXPECTED TO GO PUBLIC ON NASDAQ. ORATECH WILL HAVE GLOBAL MARKETING RIGHTS TO ORAMED'S POD ORAL PROTEIN DELIVERY TECHNOLOGY.

ORAMED ANNOUNCES TRANSFORMATIVE JOINT VENTURE TO ACCELERATE DEVELOPMENT AND COMMERCIALIZATION OF ORAL INSULIN

INITIATING PHASE 3 ORAL INSULIN TRIAL IN THE UNITED STATES UNDER A NEW PROTOCOL JV WITH CHINESE PARTNER, HTIT SCILEX SENIOR SECURED NOTE PERITECH ASSET PURCHASE & STRATEGIC OUT-LICENSING NEW YORK , FEB. 20, 2024 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (TASE: ORMP) (WWW.ORAMED.COM), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL DRUG DELIVERY PLATFORMS, TODAY ISSUED A LETTER TO SHAREHOLDERS FROM ITS PRESIDENT AND CHIEF EXECUTIVE OFFICER, NADAV KIDRON. DEAR SHAREHOLDERS, I AM PLEASED TO SHARE WITH YOU AN UPDATE REGARDING ORAMED.

ORAMED LETTER TO SHAREHOLDERS

18-MONTH LOAN WITH INTEREST RATE OF SOFR PLUS 8.5% ORAMED RECEIVES WARRANTS TO PURCHASE UP TO 17 MILLION SHARES OF SCILEX COMMON STOCK THE SENIOR SECURED NOTE WITH SCILEX REPLACES ORAMED'S PREVIOUSLY ANNOUNCED STOCK PURCHASE AGREEMENT AND DIP TERM LOAN WITH SORRENTO THERAPEUTICS NEW YORK , SEPT. 21, 2023 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (TASE:ORMP) TODAY ANNOUNCED THAT ON SEPTEMBER 21, 2023, ORAMED AND SCILEX HOLDING COMPANY("SCILEX") ENTERED INTO A SECURITIES PURCHASE AGREEMENT PURSUANT TO WHICH SCILEX ISSUED A SENIOR SECURED PROMISSORY NOTE (THE "NOTE") TO ORAMED.

ORAMED ANNOUNCES $101,875,000 SHORT-TERM SENIOR SECURED NOTE TRANSACTION WITH SCILEX HOLDING COMPANY

JV WILL HAVE GLOBAL MARKETING RIGHTS TO ORAL DRUG DELIVERY TECHNOLOGY HTIT TO INVEST $60 MILLION, ORAMED TO INVEST $10 MILLION INTO JV HTIT TO PROVIDE A SUPPLY AGREEMENT FOR ORAL INSULIN CAPSULE JV TO ADVANCE REGISTRATION OF ORAL INSULIN IN THE UNITED STATES AND OTHER COUNTRIES NEW YORK , AUG. 2, 2023 /PRNEWSWIRE/ -- ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (TASE: ORMP) (WWW.ORAMED.COM) ANNOUNCED TODAY THAT IT HAS SIGNED A NON-BINDING TERM SHEET WITH HEFEI TIANHUI BIOTECH CO., LTD. ("HTIT") TO ESTABLISH A JOINT VENTURE ("JV") BASED ON ORAMED'S ORAL DRUG DELIVERY TECHNOLOGY.

ORAMED SIGNS TERM SHEET WITH HTIT TO CREATE A JOINT VENTURE TO ADVANCE ORAL DRUG DELIVERY TECHNOLOGY GLOBALLY

BALTIMORE--(BUSINESS WIRE)--MYMD PHARMACEUTICALS, INC. (NASDAQ: MYMD) (MYMD OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY COMMITTED TO EXTENDING HEALTHY LIFESPAN, ANNOUNCED TODAY THAT ITS INVESTMENT COMPANY ORAVAX MEDICAL INC. (ORAVAX), PARTIALLY OWNED WITH ITS MAJORITY PARTNER ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (ORAMED), HAS SIGNED A COOPERATION AND PURCHASE AGREEMENT WITH VIETNAM-BASED TAN THANH HOLDINGS INVESTMENT JOINT STOCK COMPANY TO PRE-PURCHASE ORAVAXS ORAL COVID-19 VACCINE, CURRENTLY IN DEVELOPMENT. THE AGREEMENT IS FOR AN INITIAL PRE-ORDER OF 10 MILLION DOSES OF ORAL COVID-19 VACCINES FROM ORAVAX AND IS COMPRISED OF MILESTONE PAYMENTS. THE PARTIES HAVE AGREED TO NEGOTIATE POTENTIAL FOLLOW-ON ORDERS THAT COULD BE SIGNIFICANT. THE AGREEMENT GRANTS TAN THANH HOLDINGS THE RIGHT TO SELL ORAVAXS ORAL VACCINE IN DEVELOPMENT THROUGHOUT THE ASSOCIATION OF SOUTHEAST ASIAN NATIONS (ASEAN) WHICH INCLUDES VIETNAM, BRUNEI, CAMBODIA, INDONESIA, LAOS, MALAYSIA, MYANMAR, THE PHILIPPINES, SINGAPORE AND THAILAND. IN A STATEMENT, ORAMED CEO AND ORAVAX CHAIRMAN NADAV KIDRON SAID, THIS PRE-PURCHASE OF OUR ORAL COVID-19 VACCINE IN DEVELOPMENT REPRESENTS A MAJOR MILESTONE FOR ORAVAX MEDICAL AND ANOTHER STEP FORWARD IN THE IMPLEMENTATION OF OUR LONG-TERM STRATEGY. WITH THE DRAMATIC INCREASE IN POSITIVE CASES OF THE OMICRON VARIANT, THE GLOBAL NEED FOR AN ORAL VACCINE THAT PROTECTS AGAINST CURRENT AND FUTURE VARIANTS IS CRUCIAL. AN ORAL COVID-19 VACCINE WOULD SIGNIFICANTLY IMPROVE VACCINATION LOGISTICS AND REDUCE COSTS. WE VIEW TAN THANH HOLDINGS AS AN IDEAL PARTNER TO BRING OUR VACCINE TO VIETNAM AND THE ASEAN REGION. ORAVAXS ORAL VIRUS-LIKE PARTICLE (VLP) VACCINE IN DEVELOPMENT TARGETS THREE SARS COV-2 VIRUS SURFACE PROTEINS, INCLUDING PROTEINS LESS SUSCEPTIBLE TO MUTATION, THUS MAKING THE VACCINE POTENTIALLY MORE EFFECTIVE AGAINST CURRENT AND FUTURE VARIANTS OF THE COVID-19 VIRUS. ORAVAX'S VLP VACCINE TECHNOLOGY IS HIGHLY SCALABLE FOR MANUFACTURING AND IS EASI

MYMD PHARMACEUTICALS INVESTMENT COMPANY ORAVAX MEDICAL SIGNS COOPERATION AND PURCHASE AGREEMENT FOR INITIAL PRE-PURCHASE OF 10 MILLION DOSES OF ORAL COVID-19 VACCINE TO BE COMMERCIALIZED IN SOUTHEAST ASIA

BALTIMORE--(BUSINESS WIRE)--MYMD PHARMACEUTICALS, INC. (NASDAQ: MYMD) (MYMD OR THE COMPANY), A CLINICAL-STAGE PHARMACEUTICAL COMPANY COMMITTED TO EXTENDING HEALTHY LIFESPAN, ANNOUNCED TODAY THAT ITS INVESTMENT COMPANY ORAVAX MEDICAL INC. (ORAVAX), PARTIALLY OWNED WITH ITS MAJORITY PARTNER ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (ORAMED), HAS ESTABLISHED A 5050 JOINT VENTURE WITH GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. (BMV: LABB), A LEADING PHARMACEUTICAL AND PERSONAL CARE PRODUCTS COMPANY IN LATIN AMERICA WITH AN EXPANDING INTERNATIONAL PRESENCE, TO DEVELOP AND COMMERCIALIZE ORAVAXS ORAL COVID19 VACCINE CANDIDATE IN MEXICO. NADAV KIDRON, ORAMED CEO AND ORAVAX CHAIRMAN, AND RODRIGO HERRERA, GENOMMA LAB CHAIRMAN, WILL HOLD A JOINT PRESS EVENT TODAY, THURSDAY, NOVEMBER 18, 2021 AT 11:00 AM EST. THE LIVE PRESS EVENT WILL BE AVAILABLE VIA ZOOM. JOSH SILVERMAN, CHAIRMAN OF THE BOARD OF MYMD, COMMENTED, WE BELIEVE ORAVAXS VACCINE TECHNOLOGY FOR COVID-19 IS BEST IN ITS CLASS, AND THE OPPORTUNITIES FOR COMMERCIALIZING THE PRODUCT ARE FAR-REACHING. THE GLOBAL COVID-19 VACCINE MARKET IS EXPECTED TO GROW TO US$25 BILLION BY 2024, AND LATIN AMERICA REPRESENTS A SUBSTANTIAL PART. GENOMMA LABS VAST NETWORK AND MARKET PRESENCE IN LATIN AMERICA IS EXPECTED TO BE OF ENORMOUS VALUE FOR THE ROLL-OUT OF ORAVAXS VACCINE THROUGHOUT THE REGION. IN ADDITION TO LATIN AMERICA, ORAVAX IS TAKING GREAT STRIDES IN OTHER REGIONS OF THE WORLD, MR. SILVERMAN CONTINUED. ORAVAX HAS RECEIVED CLEARANCE FROM THE SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY TO BEGIN PATIENT ENROLLMENT IN A FIRST-IN-HUMAN CLINICAL TRIAL FOR ITS ORAL COVID-19 VACCINE, AND PREPARATIONS TO BEGIN THE TRIAL ARE UNDERWAY. ORAVAX IS ALSO PREPARING TO COMMENCE CLINICAL TRIALS IN ISRAEL. IN A STATEMENT, ORAMED CEO AND ORAVAX CHAIRMAN NADAV KIDRON SAID, WE ARE VERY EXCITED TO BE PARTNERING WITH GENOMMA. THE SYNERGIES BETWEEN OUR RESPECTIVE COMPANIES CORE COMPETENCIES MADE IT CLEAR THAT THE COMBINATION OF OUR PARTICULAR S

MYMD PHARMACEUTICALS INVESTMENT COMPANY ORAVAX MEDICAL AND GENOMMA LAB ANNOUNCE JOINT VENTURE TO DEVELOP AND COMMERCIALIZE ORAL COVID-19 VACCINE IN MEXICO AND DRIVE BUSINESS DEVELOPMENT IN LATIN AMERICA

BALTIMORE--(BUSINESS WIRE)--MYMD PHARMACEUTICALS, INC. (NASDAQ: MYMD) (MYMD OR THE COMPANY), A CLINICAL STAGE PHARMACEUTICAL COMPANY COMMITTED TO EXTENDING HEALTHY LIFESPAN BY FOCUSING ON DEVELOPING TWO THERAPEUTIC PLATFORMS, TODAY REPORTED THAT ITS SUBSIDIARY ORAVAX MEDICAL INC. (ORAVAX), PARTIALLY OWNED WITH ITS MAJORITY PARTNER ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (ORAMED), IS PREPARING TO COMMENCE CLINICAL TRIALS FOR ITS ORAL COVID-19 VACCINE, FIRST IN ISRAEL, THEN IN ADDITIONAL CLINICAL SITES INTERNATIONALLY. ORAVAXS COVID-19 VACCINE IS BEING DEVELOPED FOR USE BOTH AS A STANDALONE VACCINE AND AS A BOOSTER FOR PEOPLE WHO HAVE BEEN PREVIOUSLY VACCINATED FOR COVID-19. ORAMED AND MYMD ARE CURRENTLY EVALUATING SEVERAL OPTIONS WITH RESPECT TO THEIR INTEREST IN ORAVAX INCLUDING A POTENTIAL DISTRIBUTION OF ORAVAX SHARES TO BOTH ORAMED AND MYMD SHAREHOLDERS. THIS WOULD MAKE ORAVAX A PUBLICLY HELD COMPANY THAT MAY THEN APPLY FOR LISTING ON NASDAQ IF ELIGIBLE. MYMDS OWNERSHIP OF ORAVAX CONSISTS OF 13% OF ORAVAXS OUTSTANDING SHARES OF CAPITAL STOCK AND A 2.5% ROYALTY ON ALL FUTURE NET SALES. THE POTENTIAL SPIN-OFF OF ORAVAX COULD BE BENEFICIAL TO MYMD SHAREHOLDERS THROUGH OUR OWNERSHIP STAKE AND DUE TO ORAVAXS STRONG POSITION IN THE PUBLIC MARKETS AS AN ORAL VACCINE DEVELOPER, SAID JOSH SILVERMAN, CHAIRMAN OF THE BOARD OF MYMD PHARMACEUTICALS. ORAVAXS STUDIES OF ITS VLP VACCINE FOR COVID-19 SHOULD BE OF PARTICULAR INTEREST TO MYMD SHAREHOLDERS GIVEN OUR OWN UPCOMING PHASE 2 CLINICAL TRIAL OF MYMD-1 TO TREAT IMMUNE MEDIATED DEPRESSION AND CYTOKINE ELEVATION IN COVID-19 PATIENTS. WE ARE EXCITED ABOUT THE POSSIBILITIES FOR BOTH TECHNOLOGIES IN THE GLOBAL FIGHT AGAINST COVID-19. AS A TRIPLE ANTIGEN TARGETING THREE SARS COV-2 VIRUS SURFACE PROTEINS INSTEAD OF ONE, INCLUDING PROTEINS LESS SUSCEPTIBLE TO MUTATION, MYMD BELIEVES THAT ORAVAXS COVID-19 VACCINE CANDIDATE COULD BE A BETTER CANDIDATE TO PROVIDE PROTECTION EVEN AGAINST EMERGING MUTATED VIRUSES. THE ORAL DELIVERY O

Oramed Pharmaceuticals Inc.

ORMP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Oramed Pharmaceuticals Inc.

ORMP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ORMP